Treatment Information

Back

Liver Cancer treatment details. Chemotherapy.

California Pacific Medical Center, San Francisco, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:San Francisco, CA
Treatments:ChemotherapyHospital:California Pacific Medical Center
Drugs:Journal:Link
Date:Jul 2007

Description:

Patients: This phase III study involved 445 patients with unresectable or metastatic hepatocellular carcinoma (liver cancer).

Treatment: The patients were divided into two groups; one half received doxorubicin and the others received nolatrexed. Both of these drugs are chemotherapy.

Toxicity: Grade 3 and 4 adverse events included anemia, thrombocytopenia, neutropenia, leukopenia, fatigue, stomatitis, abdominal pain, anorexia, skin reaction, vomiting and diarrhea. Toxicity was greater in the patients receiving nolatrexed.

Results: The median overall survival for patient s receiving doxorubicin was 32.3 weeks (7.4 months), and for patients receiving nolatrexed, the median overall survival was 22.3 weeks (5.1 months).

Support: Research funds were provided by Eximias Pharmaceutical Corporation, which developed and manufactures nolatrexed. Nolatrexed is also known as NOL and THYMITAQ‚.

Correspondence: Dr. Robert Gish





Back